Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
This study has been completed.
Study NCT00189917   Information provided by Bavarian Nordic

First Received on September 11, 2005.   Last Updated on October 10, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Dermatitis, Atopic
Hay Fever
Additional conditions recognized in this trial
Dermatitis
Rhinitis, Allergic, Seasonal
Smallpox
More general conditions related to this trial
DNA Virus Infections
Genetic Diseases, Inborn
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Nose Diseases
Otorhinolaryngologic Diseases
Poxviridae Infections
Respiratory Hypersensitivity
Respiratory Tract Diseases
Rhinitis
Skin Diseases
Skin Diseases, Eczematous
Skin Diseases, Genetic
Virus Diseases
Interventions listed in this trial
IMVAMUNE (MVA-BN)
Sponsors listed in this trial
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services